Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 5,231 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Opioid Use Disorder
Interventions: BI 1356225, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more

Conditions: Acute Apical Abscess, Pain, Acute
Interventions: Valacyclovir 500 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cervical Spine Disease, Psychological Impairment
Interventions: Cognitive Behavioral Therapy, Sham Therapy; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Disease
Interventions: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; Drug
Lead sponsor: Pharma Two B Ltd.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more

Conditions: Healthy Volunteers
Interventions: ABBV-243, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Torsades de Pointes
Interventions: VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more

Conditions: Drug-resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • Little Rock, Arkansas • La Jolla, California + 21 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK5784283, Placebo, Standard of care; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Doral, Florida • Lake Charles, Louisiana • Humble, Texas + 2 more

Conditions: Autism Spectrum Disorder
Interventions: Placebo, RG7314; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more

Conditions: Delirium
Interventions: Melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: Scripps Health; Other
Eligibility: 65 Years to 100 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Subjects
Interventions: PF-06648671, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Autoimmune Autonomic Ganglionopathy (AAG)
Interventions: Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Bethesda, Maryland • Boston, Massachusetts • Rochester, Minnesota + 3 more

Conditions: Hepatitis b Virus, Hepatitis B
Interventions: HepB mAb19, Sterile Saline; Biological · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: GSK4527226, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 21
States / cities: San Diego, California • Lake Mary, Florida • Lake Worth, Florida + 16 more

Conditions: Advanced Stage Parkinson's Disease
Interventions: Levodopa (Pardoprunox), Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 12 more

Conditions: Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions: N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging; Drug · Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions: Valproate, Placebo, Patch; Drug · Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Persistent Asthma
Interventions: QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Metabolic Syndrome
Interventions: Blueberry Powder; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Chronic Stable Plaque Psoriasis
Interventions: Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more

Conditions: Female Orgasmic Disorder
Interventions: Placebo, Low dose TBS-2, Medium dose TBS-2, High dose TBS-2; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 37 more

Search by objective public record fields.

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

Valacyclovir in Pain Management of Acute Apical Abscesses

The Confounding Burden of Psychological Impairments in Cervical Spine Surgery

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

Melatonin and Sleep in Preventing Delirium in the Hospital

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Valproate for the Treatment of Residual Amblyopia

Efficacy, Safety, and Pharmacokinetics of QAW039

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder